• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Ontrak Health Announces 2025 First Quarter Financial Results

    5/20/25 4:05:00 PM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care
    Get the next $OTRK alert in real time by email
    • Q1 Revenue of $2.0 million, down 25% year over year
    • Q1 Operating loss of $(5.9) million, a 37% increase year over year
    • Q1 Adjusted EBITDA of $(4.3) million, a 28% decline year over year
    • Company announces securing a $10.0 million financing commitment from Acuitas Capital LLC
    • Company announces recertification by the National Committee for Quality Assurance (NCQA) as a Credentials Verification Organization (CVO)
    • Company to Host Conference Call at 4:30 pm ET Today

    Ontrak, Inc. (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and technology-enabled behavioral healthcare company, today reported its financial results for the first quarter ended March 31, 2025.

    Management Commentary

    Brandon LaVerne, Ontrak Health's Chief Executive Officer, stated, "We are thrilled to report that membership in our Ontrak programs has nearly doubled year over year, validating our multi-solution approach across Medicare Advantage, Medicaid, and Commercial populations. Our AI-driven Advanced Engagement System has transformed how we deliver care, enabling unprecedented operational efficiency while maintaining our focus on the human elements that drive meaningful outcomes. Our successful implementations at Intermountain Health and our Northeast Regional Plan, coupled with our optimism on converting prospects in our pipeline, provide a path to doubling our run-rate revenue in 2025."

    First Quarter 2025 Financial Results Highlights

    • Revenue for the first quarter of 2024 was $2.0 million, representing a 25% decrease compared to the same period in 2024.
    • Operating loss for the first quarter of 2024 was $(5.9) million compared to an operating loss of $(4.3) million for the same period in 2024.
    • Adjusted EBITDA for the first quarter of 2024 was $(4.3) million compared to adjusted EBITDA of $(3.4) million for the same period in 2024.
    • Net loss for the first quarter of 2025 was $(6.9) million, or a $(1.65) diluted net loss per common share (after deduction for undeclared preferred stock dividends), compared to net loss of $(4.5) million, or a $(1.65) diluted net loss per common share (after deduction for undeclared preferred stock dividends) for the same period in 2023.
    • Non-GAAP net loss for the first quarter of 2025 was $(5.5) million, or a $(1.40) non-GAAP diluted net loss per common share (after deduction for undeclared preferred stock dividends), compared to non-GAAP net loss of $(3.8) million, or a $(1.49) non-GAAP diluted net loss per common share (after deduction for undeclared preferred stock dividends) for the same period in 2024.

    Adjusted EBITDA, non-GAAP net loss and non-GAAP diluted net loss per common share are non-GAAP financial measures. See our description and reconciliation of such non-GAAP measures at the end of this release.

    First Quarter 2025 and Recent Operating Highlights

    • Total enrolled members in our WholeHealth+ program numbered 1,578 at the end of Q1 2025, compared to 1,409 at the end of Q4 2024 and 1,521 at the end of Q1 2024. Total enrolled members in Ontrak Engage, one of the segmented solutions within WholeHealth+ which we began offering on an à la carte basis in Q2 2024, numbered 1,587 at the end of Q1 2025, compared to 716 at the end of Q4 2024.
    • Total callable outreach pool for WholeHealth+ was 7,319 at March 31, 2025 compared to 4,908 at December 31, 2024 and 5,057 at March 31, 2024. Total callable outreach pool for Ontrak Engage was 22,152 at March 31, 2025 compared to 20,648 at December 31, 2024.
    • On May 19, 2025, the Company and Acuitas Capital LLC ("Acuitas") entered into an agreement relating to the Keep Well Agreement pursuant to which, among other things, Acuitas i) committed to purchase up to an additional $5.0 million in principal amount of Demand Notes (the "May 2025 Convertible Demand Notes") and up to $5.0 million in principal amount of senior secured non-convertible promissory notes (the "Non-Convertible Demand Notes") from the Company, and ii) agreed not to exercise its right to require that any amounts due under any Demand Note or Non-Convertible Demand Note be paid until the earlier of (a) September 1, 2026 and (b) 30 days following the date on which all $5.0 million in principal amount of Non-Convertible Demand Notes has been purchased.
    • In April 2025, the Company announced it has been re-certified by the National Committee for Quality Assurance (NCQA), a recognized leader in healthcare quality assessment, evaluation, and certification, as a Credentials Verification Organization (CVO) for the element of license to practice. This recertification reaffirms Ontrak's ongoing commitment to maintaining the highest standards of quality and compliance across its suite of healthcare solutions, helping health plan customers effectively meet their accreditation goals. Ontrak's renewed NCQA certification will extend through April 22, 2027.
    • In April 2025, the Company announced that a new affiliated practice association has secured the official Medicaid designation in two new states, which will enable Ontrak to operate as a direct value-based provider in addition to its historical operations as a vendor. As a value-based care provider, Ontrak can align the quality outcomes and HEDIS measures with medical cost savings and financial incentives that it shares with payor partners. In addition, classification as a value based provider gives payors greater flexibility to partner with Ontrak through a model that allows for fees to become part of the medical cost ratio rather than an administrative vendor fee. For Medicaid plans, it will allow for Ontrak to bill codes that are reimbursable at the State level. This shift is further enabling additional pipeline opportunities and provides payors optionality and flexibility in working with Ontrak.
    • In February 2025, the Company announced the signing of an extension of its strategic partnership with Sentara Health Plans for an additional three years through December 2027, following three successful expansions throughout 2024, including the expansion of WholeHealth+ to a larger Commercial membership, and introduction of Ontrak's Engage solution to Sentara Health Plans' Commercial fully insured and certain self-funded members, as well as the Marketplace membership. These expansions have significantly broadened the reach and support for members, addressing their physical and behavioral health needs, and social determinants of health. With this expansion, Ontrak began offering its Quality solution to close HEDIS gaps in care as part of its WholeHealth+ and Engage solutions to enrolled Sentara Health Plans members.

    Financial Outlook

    The following outlook is based on information available as of the date of this press release and is subject to change in the future.

    For the quarter ending June 30, 2025, the Company estimates revenue in the range of $2.2 million to $2.6 million.

    Conference Call & Webcast Details

    The Company will host a conference call/webcast today at 4:30 pm ET/1:30 pm PT. Investors, analysts, employees and the general public can access the call by registering online for dial-in information or via live audio webcast at: https://ontrakhealth.com/investors/presentations-events. Participants interested in dialing in to the conference call are requested to register a day in advance or at a minimum 15 minutes before the start of the call to obtain a unique pin for the call.

    A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

    About Ontrak, Inc.

    Ontrak Health (NASDAQ:OTRK) is a value-based behavioral healthcare company that identifies and engages people with unmet health needs using its proprietary Advanced Engagement System to improve clinical outcomes and reduce total cost of care. Ontrak uniquely identifies, engages, and delivers care to the most vulnerable members of the behavioral health population who would otherwise fall through the cracks of the healthcare system. Through our Advanced Engagement System, we achieve higher engagement rates with individuals with anxiety, depression, substance use disorder and chronic disease by delivering personalized care coaching and customized care pathways that help them receive the treatment and advocacy they need, despite the socio-economic, medical and health system barriers that exacerbate the severity of their comorbid illnesses. The company's whole-person approach integrates AI, predictive analytics, comprehensive clinical and claims data, patient-generated information, and digital interfaces with care coach engagements to deliver improved member health, better healthcare system utilization, and durable outcomes and savings to healthcare payors.

    Learn more at www.ontrakhealth.com.

    Forward-Looking Statements

    This press release contains "forward-looking" statements that are based on the Company's beliefs and assumptions and on information currently available to the Company on the date of this press release and are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as "may," "will," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plan," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words. Forward-looking statements may include, but are not limited to, the Company's belief that it will be successful in returning to sustained growth, that its strategy will accelerate the Company's return to growth by converting new customers and expand with existing customers, the Company's ability to convert its pipeline of prospects into active customers, the Company's ability to maximize its differentiated platform and deliver return on investment for customers, the Company's revenue on a per member per month basis, gross margin estimates and the Company's estimated revenue for quarter ending June 30, 2025. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements, including, without limitation, risks related to: the Company's ability to successfully execute on its strategy and business plan; the Company's ability to increase its revenue and efficiently manage expenses and achieve profitability; the Company's high customer concentration and the ability of its customers to terminate their contracts for convenience; the adequacy of the Company's existing cash resources and anticipated capital commitments and future cash requirements to enable the Company to continue as a going concern; Company's ability to access the financing provided by the financing commitment and the potential benefits to the Company of such financing; the Company's ability to raise additional capital when needed; difficulty enrolling new members and maintaining existing members in the Company's programs; the effectiveness of the Company's treatment programs; lower than anticipated eligible members under the Company's contracts; the Company's dependence on key personnel and the Company's ability to recruit and retain key personnel; the Company's ability to maintain the listing of its stock on Nasdaq; the federal jury's conviction of the Company's largest stockholder and former Chief Executive Officer and Chairman of one count of securities fraud and two counts of insider trading, and whether governmental authorities will institute separate investigations or proceedings against the Company and/or its current or former executives and/or directors; substantial regulation in the health care industry; changes in regulations or issuance of new regulations or interpretations; the Company's limited operating history; difficulty in developing, exploiting and protecting proprietary technologies; business disruption and related risks; general economic conditions, nationally and globally, and their effect on the market for our service; intense competition and competitive pressures and trends in the Company's industry and the Company's ability to successfully compete; changes in laws, regulations, or policies; and risks related to the Company's ability to realize the potential benefits of and to effectively integrate acquisitions. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company's most recent Securities and Exchange Commission filings which are available on its website at http://www.sec.gov. Forward-looking statements are current only as of the date they are made and the Company assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

    Non-GAAP Financial Measures

    To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles, or GAAP, the Company has provided in this press release and the quarterly conference call held on the date hereof certain non-GAAP financial measures. The non-GAAP financial measures presented include EBITDA, Adjusted EBITDA, Non-GAAP net loss, and Non-GAAP net loss per common share, which are not U.S. GAAP financial measures. We believe that the presentation of these financial measures enhances an investor's understanding of our financial performance. We further believe that these financial measures are useful financial metrics to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business.

    EBITDA consists of net loss before interest, taxes, depreciation and amortization expenses. Adjusted EBITDA consists of net loss before interest, taxes, depreciation, amortization, stock-based compensation, restructuring, severance and related costs, and gain/loss on change in fair value of warrant liability. We believe that making such adjustments provides investors meaningful information to understand our results of operations and the ability to analyze our financial and business trends on a period-to-period basis.

    Non-GAAP net loss consists of net loss adjusted for stock-based compensation, restructuring, severance and related costs, and gain/loss on change in fair value of warrant liability. Non-GAAP net loss per common share consists of loss per share adjusted for non-GAAP net loss attributable to common stockholders. We believe that making such adjustments provides investors meaningful information to understand our results of operations and the ability to analyze our financial and business trends on a period-to-period basis.

    We believe the above non-GAAP financial measures are commonly used by investors to evaluate our performance and that of our competitors. However, our use of the term EBITDA, Adjusted EBITDA, Non-GAAP net loss and Non-GAAP net loss per common share may vary from that of others in our industry. None of EBITDA, Adjusted EBITDA, Non-GAAP net loss or Non-GAAP net loss per common share should be considered as an alternative to net loss before taxes, net loss, net loss per common share or any other performance measures derived in accordance with U.S. GAAP as measures of performance.

    See the Reconciliation of Non-GAAP Measures table at the end of this press release for a reconciliation of the Non-GAAP financial measures to U.S. GAAP financial measures.

    ONTRAK, INC.

    Consolidated Statements of Operations

    (in thousands, except per share data)

     

     

     

    Three Months Ended

    March 31,

     

     

    2025

     

    2024

    Revenue

     

    $

    2,017

     

     

    $

    2,680

     

    Cost of revenue

     

     

    1,271

     

     

     

    975

     

    Gross profit

     

     

    746

     

     

     

    1,705

     

     

     

     

     

     

    Operating expenses:

     

     

     

     

    Research and development

     

     

    1,408

     

     

     

    1,078

     

    Sales and marketing

     

     

    564

     

     

     

    532

     

    General and administrative

     

     

    4,624

     

     

     

    4,078

     

    Restructuring, severance and related costs

     

     

    —

     

     

     

    290

     

    Total operating expenses

     

     

    6,596

     

     

     

    5,978

     

    Operating loss

     

     

    (5,850

    )

     

     

    (4,273

    )

     

     

     

     

     

    Other expense, net

     

     

    —

     

     

     

    (2

    )

    Interest expense, net

     

     

    (1,041

    )

     

     

    (183

    )

    Loss before income taxes

     

     

    (6,891

    )

     

     

    (4,458

    )

    Income tax expense

     

     

    —

     

     

     

    —

     

    Net loss

     

     

    (6,891

    )

     

     

    (4,458

    )

    Dividends on preferred stock - undeclared

     

     

    (2,239

    )

     

     

    (2,239

    )

    Net loss attributable to common stockholders

     

    $

    (9,130

    )

     

    $

    (6,697

    )

     

     

     

     

     

    Net loss per common share, basic and diluted

     

    $

    (1.65

    )

     

    $

    (1.65

    )

     

     

     

     

     

    Weighted-average common shares outstanding, basic and diluted

     

     

    5,517

     

     

     

    4,059

     

    ONTRAK, INC.

    Consolidated Balance Sheets

    (in thousands, except share and per share data)

     

     

    March 31,

    2025

     

    December 31,

    2024

    Assets

    (unaudited)

     

     

    Current assets:

     

     

     

    Cash

    $

    4,087

     

     

    $

    5,710

     

    Accounts receivable, net

     

    602

     

     

     

    1,012

     

    Unbilled receivables

     

    879

     

     

     

    595

     

    Deferred costs

     

    179

     

     

     

    178

     

    Prepaid expenses and other current assets

     

    2,162

     

     

     

    2,065

     

    Total current assets

     

    7,909

     

     

     

    9,560

     

    Long-term assets:

     

     

     

    Property and equipment, net

     

    454

     

     

     

    490

     

    Goodwill

     

    5,713

     

     

     

    5,713

     

    Other assets

     

    4,064

     

     

     

    5,167

     

    Operating lease right-of-use assets

     

    131

     

     

     

    145

     

    Total assets

    $

    18,271

     

     

    $

    21,075

     

    Liabilities and stockholders' equity

     

     

     

    Current liabilities:

     

     

     

    Accounts payable

    $

    725

     

     

    $

    179

     

    Accrued compensation and benefits

     

    824

     

     

     

    558

     

    Deferred revenue

     

    19

     

     

     

    18

     

    Demand notes payable, net

     

    7,037

     

     

     

    6,008

     

    Current portion of operating lease liabilities

     

    72

     

     

     

    68

     

    Other accrued liabilities

     

    2,379

     

     

     

    1,949

     

    Total current liabilities

     

    11,056

     

     

     

    8,780

     

    Long-term liabilities:

     

     

     

    Long-term debt, net

     

    2,489

     

     

     

    2,327

     

    Long-term operating lease liabilities

     

    79

     

     

     

    98

     

    Total liabilities

     

    13,624

     

     

     

    11,205

     

    Commitments and contingencies

     

     

     

    Stockholders' equity:

     

     

     

    Preferred stock, $0.0001 par value; 50,000,000 shares authorized; 3,770,265 shares issued and outstanding at each of March 31, 2025 and December 31, 2024

     

    —

     

     

     

    —

     

    Common stock, $0.0001 par value; 500,000,000 shares authorized; 4,217,848 shares issued and outstanding at each of March 31, 2025 and December 31, 2024

     

    7

     

     

     

    7

     

    Additional paid-in capital

     

    552,253

     

     

     

    550,585

     

    Accumulated deficit

     

    (547,613

    )

     

     

    (540,722

    )

    Total stockholders' equity

     

    4,647

     

     

     

    9,870

     

    Total liabilities and stockholders' equity

    $

    18,271

     

     

    $

    21,075

     

    ONTRAK, INC.

    Consolidated Statements of Cash Flows

    (in thousands)

     

     

    For the Three Months Ended

    March 31,

     

    2025

     

    2024

    Cash flows from operating activities

     

     

     

    Net loss

    $

    (6,891

    )

     

    $

    (4,458

    )

    Adjustments to reconcile net loss to net cash used in operating activities:

     

     

     

    Stock-based compensation expense

     

    1,421

     

     

     

    352

     

    Paid-in-kind interest expense

     

    586

     

     

     

    112

     

    Depreciation expense

     

    104

     

     

     

    198

     

    Amortization expense

     

    454

     

     

     

    100

     

    Change in fair value of warrant liability

     

    —

     

     

     

    2

     

    Changes in operating assets and liabilities:

     

     

     

    Accounts receivable

     

    411

     

     

     

    (241

    )

    Unbilled receivables

     

    (284

    )

     

     

    (25

    )

    Prepaid expenses and other assets

     

    (84

    )

     

     

    365

     

    Accounts payable

     

    545

     

     

     

    104

     

    Deferred revenue

     

    1

     

     

     

    146

     

    Leases liabilities

     

    (16

    )

     

     

    (13

    )

    Other accrued liabilities

     

    1,030

     

     

     

    99

     

    Net cash used in operating activities

     

    (2,723

    )

     

     

    (3,259

    )

    Cash flows from investing activities

     

     

     

    Purchase of property and equipment

     

    (58

    )

     

     

    (37

    )

    Net cash used in investing activities

     

    (58

    )

     

     

    (37

    )

    Cash flows from financing activities

     

     

     

    Proceeds from Demand Notes

     

    1,500

     

     

     

    —

     

    Proceeds from warrants exercised

     

    —

     

     

     

    523

     

    Financed insurance premium payments

     

    (342

    )

     

     

    (528

    )

    Payment of taxes related to net-settled stock awards

     

    —

     

     

     

    —

     

    Net cash provided by (used in) financing activities

     

    1,158

     

     

     

    (5

    )

    Net change in cash and restricted cash

     

    (1,623

    )

     

     

    (3,301

    )

    Cash at beginning of period

     

    5,710

     

     

     

    9,701

     

    Cash at end of period

    $

    4,087

     

     

    $

    6,400

     

     

     

     

     

    Supplemental disclosure of cash flow information:

     

     

     

    Interest paid

    $

    17

     

     

    $

    30

     

    Non-cash financing and investing activities:

     

     

     

    Debt issuance costs

    $

    —

     

     

    $

    10,495

     

    Warrants issued in connection with Demand Notes

     

    247

     

     

     

    —

     

    Finance lease and accrued purchases of property and equipment

     

    —

     

     

     

    4

     

    Common stock issued to settle contingent consideration

     

    —

     

     

     

    64

     

    ONTRAK, INC.

    Reconciliation of Non-GAAP Measures

    (in thousands, except per share data)

     

    Reconciliation of Operating Loss to EBITDA and Adjusted EBITDA

     

     

     

    Three Months Ended

    March 31,

     

     

    2025

     

    2024

    Operating loss

     

    $

    (5,850

    )

     

    $

    (4,273

    )

    Depreciation expense

     

     

    104

     

     

     

    198

     

    Amortization expense (1)

     

     

    14

     

     

     

    61

     

    EBITDA

     

     

    (5,732

    )

     

     

    (4,014

    )

    Stock-based compensation expense

     

     

    1,421

     

     

     

    352

     

    Restructuring, severance and related costs (2)

     

     

    —

     

     

     

    290

     

    Adjusted EBITDA

     

    $

    (4,311

    )

     

    $

    (3,372

    )

    Reconciliation of Net Loss to Non-GAAP Net Loss; and Net Loss per Common Share to Non-GAAP Net Loss per Common Share

     

     

     

    Three Months Ended

    March 31,

     

     

    2025

     

    2024

    Net loss

     

    $

    (6,891

    )

     

    $

    (4,458

    )

    Stock-based compensation expense

     

     

    1,421

     

     

     

    352

     

    Restructuring, severance and related costs (2)

     

     

    —

     

     

     

    290

     

    Loss on change in fair value of warrant liability

     

     

    —

     

     

     

    2

     

    Non-GAAP net loss

     

     

    (5,470

    )

     

     

    (3,814

    )

    Dividends on preferred stock - undeclared

     

     

    (2,239

    )

     

     

    (2,239

    )

    Non-GAAP net loss attributable to common stockholders

     

    $

    (7,709

    )

     

    $

    (6,053

    )

     

     

     

     

     

    Net loss per common share - basic and diluted

     

    $

    (1.65

    )

     

    $

    (1.65

    )

    Non-GAAP net loss per common share - basic and diluted

     

     

    (1.40

    )

     

     

    (1.49

    )

    Weighted-average common shares outstanding - basic and diluted

     

     

    5,517

     

     

     

    4,059

     

    _______________________

    (1)

    Relates to operating and financing right-of-use assets and acquired intangible assets.

    (2)

    Includes one-time severance and related benefit costs related to reduction in workforce plan announced in February 2024 as part of Company's continued cost savings measure.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250520951370/en/

    For Investors:

    Ryan Halsted

    Gilmartin Group

    [email protected]

    Get the next $OTRK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OTRK

    DatePrice TargetRatingAnalyst
    12/5/2023$4.00Buy
    ROTH MKM
    3/9/2022$13.00 → $2.50Hold
    Canaccord Genuity
    3/9/2022$11.00 → $2.00Sector Perform
    RBC Capital
    8/20/2021$35.00 → $9.00Market Perform → Underperform
    Cowen & Co.
    8/20/2021$15.00Buy → Neutral
    B. Riley Securities
    More analyst ratings

    $OTRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Peizer Terren S

      4 - Ontrak, Inc. (0001136174) (Issuer)

      5/20/25 5:31:02 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 4 filed by Large owner Peizer Terren S

      4 - Ontrak, Inc. (0001136174) (Issuer)

      4/1/25 9:24:56 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 4 filed by Director Sherman Michael Edward

      4 - Ontrak, Inc. (0001136174) (Issuer)

      1/6/25 8:08:28 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care

    $OTRK
    Financials

    Live finance-specific insights

    See more
    • Ontrak Health Announces 2025 First Quarter Financial Results

      Q1 Revenue of $2.0 million, down 25% year over year Q1 Operating loss of $(5.9) million, a 37% increase year over year Q1 Adjusted EBITDA of $(4.3) million, a 28% decline year over year Company announces securing a $10.0 million financing commitment from Acuitas Capital LLC Company announces recertification by the National Committee for Quality Assurance (NCQA) as a Credentials Verification Organization (CVO) Company to Host Conference Call at 4:30 pm ET Today Ontrak, Inc. (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and technology-enabled behavioral healthcare company, today reported its financial results for the first quarter ended March 31, 2025. Manageme

      5/20/25 4:05:00 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Ontrak Health to Report 2025 First Quarter Financial Results on May 20, 2025

      Ontrak Health (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today announced it will report financial results for the first quarter 2025 on Tuesday, May 20, 2025, after market close. Company management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Conference Call & Webcast Details The conference call can be accessed by registering online for dial-in information or via live audio webcast at: https://ontrakhealth.com/investors/presentations-events . Participants interested in dialing in to the conference call are requested to register a day in advance or at a minimum 15 minutes before

      5/19/25 4:30:00 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Ontrak Health to Report 2024 Fourth Quarter Financial Results on April 14, 2025

      Ontrak Health (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today announced it will report financial results for the fourth quarter 2024 on Monday, April 14, 2025, after market close. Company management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Conference Call & Webcast Details The conference call can be accessed by registering online for dial-in information or via live audio webcast at: https://ontrakhealth.com/delivering-a-healthier-future-for-all/presentations-events/. Participants interested in dialing in to the conference call are requested to register a day in advance or

      4/10/25 4:05:00 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care

    $OTRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ontrak Inc.

      SC 13G/A - Ontrak, Inc. (0001136174) (Subject)

      11/14/24 4:24:03 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Ontrak Inc.

      SC 13D/A - Ontrak, Inc. (0001136174) (Subject)

      10/3/24 6:37:08 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Ontrak Inc.

      SC 13D/A - Ontrak, Inc. (0001136174) (Subject)

      8/30/24 5:15:15 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care

    $OTRK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ontrak Health Announces 2025 First Quarter Financial Results

      Q1 Revenue of $2.0 million, down 25% year over year Q1 Operating loss of $(5.9) million, a 37% increase year over year Q1 Adjusted EBITDA of $(4.3) million, a 28% decline year over year Company announces securing a $10.0 million financing commitment from Acuitas Capital LLC Company announces recertification by the National Committee for Quality Assurance (NCQA) as a Credentials Verification Organization (CVO) Company to Host Conference Call at 4:30 pm ET Today Ontrak, Inc. (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and technology-enabled behavioral healthcare company, today reported its financial results for the first quarter ended March 31, 2025. Manageme

      5/20/25 4:05:00 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Ontrak Secures Financing Commitment to Fuel Growth and Innovation

      Ontrak, Inc. (NASDAQ:OTRK), a leading value-based behavioral healthcare company powered by proprietary AI and engagement technology, announced it has secured a $10 million financing commitment from Acuitas Capital, LLC. This financing commitment will support Ontrak's continued growth and innovation in delivering comprehensive behavioral healthcare solutions and is structured to provide Ontrak with the necessary capital to expand its customer base while continuing to drive further advancements in its AI and digital capabilities. The commitment contemplates that Ontrak may raise additional financing from third parties to further support its growth initiatives. Brandon LaVerne, Chief Executiv

      5/20/25 8:00:00 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Ontrak Health to Report 2025 First Quarter Financial Results on May 20, 2025

      Ontrak Health (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today announced it will report financial results for the first quarter 2025 on Tuesday, May 20, 2025, after market close. Company management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Conference Call & Webcast Details The conference call can be accessed by registering online for dial-in information or via live audio webcast at: https://ontrakhealth.com/investors/presentations-events . Participants interested in dialing in to the conference call are requested to register a day in advance or at a minimum 15 minutes before

      5/19/25 4:30:00 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care

    $OTRK
    SEC Filings

    See more
    • SEC Form 10-Q filed by Ontrak Inc.

      10-Q - Ontrak, Inc. (0001136174) (Filer)

      5/20/25 4:08:00 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Ontrak Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Ontrak, Inc. (0001136174) (Filer)

      5/20/25 4:05:48 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Ontrak Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Ontrak, Inc. (0001136174) (Filer)

      5/20/25 8:02:18 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care

    $OTRK
    Leadership Updates

    Live Leadership Updates

    See more
    • Ontrak Names James Messina to its Board of Directors

      Ontrak, Inc. (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today announced the appointment of James Messina as a non-Executive Director to its board. Mr. Messina is a Co-Founder and General Partner of Seattle Hill Ventures and x4 Capital Partners, which invest in, and support, startup ventures by providing business development, marketing, operating and technology support. Previously, Mr. Messina was the Executive Vice President and Chief Operating Officer for Premera Blue Cross ("Premera"). He was responsible for effectively servicing the needs of Premera's customers with oversight of all operational functions, from customer serv

      8/30/22 8:00:00 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Ontrak Names Dr. Robert Accordino Chief Medical Officer

      Mental Healthcare Leader and Harvard Medical School Faculty Member Joins Ontrak Ontrak, Inc (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today announced the appointment of Dr. Robert Accordino as Ontrak's Chief Medical Officer, effective September 27, 2021. Dr. Accordino joins Ontrak from Quartet Health where he served as the company's most senior clinician and Chief Mental Health Officer. He practices psychiatry and is on the faculty of Harvard Medical School and Massachusetts General Hospital. Dr. Accordino will report to Jonathan Mayhew, CEO, who joined Ontrak from CVS Health earlier this year. "Dr. Accordino's reputation in

      9/9/21 8:00:00 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Arik Hill Joins Ontrak as Chief Information Officer

      Former Accenture and KPMG Healthcare Expert Brings Proven Leadership Experience In Behavioral Health Digital Transformation Ontrak, Inc (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today announced the appointment of Arik Hill as Ontrak's first Chief Information Officer, effective August 30, 2021. Mr. Hill will report to Jonathan Mayhew, CEO, who joined Ontrak from CVS Health earlier this year. "As Chief Information Officer at The New York Foundling, a fast growing organization that collaborates with over 250,000 behavioral healthcare partners across the country, Arik led the development of digital platforms and applications th

      8/12/21 8:00:00 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care

    $OTRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Ontrak with a new price target

      ROTH MKM initiated coverage of Ontrak with a rating of Buy and set a new price target of $4.00

      12/5/23 8:03:01 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Canaccord Genuity reiterated coverage on Ontrak with a new price target

      Canaccord Genuity reiterated coverage of Ontrak with a rating of Hold and set a new price target of $2.50 from $13.00 previously

      3/9/22 9:09:19 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • RBC Capital reiterated coverage on Ontrak with a new price target

      RBC Capital reiterated coverage of Ontrak with a rating of Sector Perform and set a new price target of $2.00 from $11.00 previously

      3/9/22 7:43:55 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care